The U.S. market for branded prescription drugs for acne was estimated to be approximately $2.6 billion for the 12 months ended March 31, 2014, of which $1.6 billion was attributed to topical drugs such as Epiduo and Aczone and $1 billion was attributed to oral drugs. Orally administered Solodyn is the brand name for an antibiotic […]
In a previous article, we discussed Bind Therapeutics (NASDAQ:BIND), a company developing a nano-drug delivery technology for Docetaxel, one of the most commonly used cancer chemotherapy drugs approved for breast cancer, head and neck cancer, and gastric cancer. Another company we highlighted, Oasmia (STO:OASM), is doing much the same thing. One company with a nano-drug delivery platform looking to […]
RNA Interference (RNAi) is a new approach in the development of specific targeted therapies against both rare diseases and cancer. Historically, the pharmaceutical industry has developed two fundamental classes of drugs that can address well-defined targets: small molecules and antibodies. Both of these drug classes have been very successful but are limited in the nature of the […]
In a previous article, we discussed Bind Therapeutics, a company developing a nano-drug delivery technology for Docetaxel, one of the most commonly used cancer chemotherapy drugs approved for breast cancer, head and neck cancer, and gastric cancer. Another publicly traded Swedish company offering a similar value proposition is Oasmia (STO:OASM). About Oasmia Founded in 1999, Swedish company Oasmia (STO:OASM) […]
In previous articles, we have discussed the potential of nanotechnology-enabled drug delivery systems such as those offered by Nanoviricides and Bind Therapeutics. One private company funded by the United States Department of Defense (USDOD), Nanotherapeutics, is targeting a broad range of unique applications with their nanotechnology-enabled drug delivery systems. About Nanotherapeutics Little information seems to be […]
Around the time nanotechnology became a buzzword among investors in 2004, much discussion was had around the potential of nano drug delivery. Companies such as SkyePharma and Flamel were discussed as having potential but neither company has succeeded yet in launching a blockbuster nano drug. One company however is bringing nano drug delivery back into […]
About pSivida One company that was heavily discussed in the Nanalyze forums is pSivida (NASDAQ:PSDV), an Australian company with a platform drug delivery system that according to the company “relies on nano structuring to achieve optimal drug delivery”. pSivida is a provider of miniaturized, sustained-release drug delivery products with an intellectual property portfolio of 150 patents. […]
In a previous article titled “What’s happening with Obducat“, we discussed a company that attracted a great deal of attention from nanotechnology investors during the nanotechnology hype of 2004. Another such company is Starpharma (OTCMKTS: SPHRY). Starpharma, an Australian biotech company which generated a great deal of attention during the nanotechnology hype of 2004 by developing […]